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Objectives This study sought to investigate the feasibility and safety of percutaneous management
of vascular complications after transcatheter aortic valve implantation (TAVI).
Background Vascular complications after TAVI are frequent and outcomes after percutaneous man-
agement of these adverse events not well established.
Methods Between August 2007 and July 2010, 149 patients underwent transfemoral TAVI using a
percutaneous approach. We compared outcomes of patients undergoing percutaneous management
of vascular complications with patients free from vascular complications and performed duplex ul-
trasonography, ﬂuoroscopy, and multislice computed tomography during follow-up.
Results A total of 27 patients (18%) experienced vascular complications consisting of incomplete
arteriotomy closure (n  19, 70%), dissection (n  3, 11%), arterial perforation (n  3, 11%), arterial
occlusion (n  1, 4%), and pseudoaneurysm (n  1, 4%). Percutaneous stent graft implantation was
successful in 21 of 23 (91%) patients, whereas 2 patients were treated by manual compression,
2 patients underwent urgent surgery, and 2 patients required delayed surgery. Rates of major ad-
verse cardiac events at 30 days were similar among patients undergoing percutaneous management
of vascular complications and those without vascular complications (9% vs. 8%, p  1.00). After a
median follow-up of 10.9 months, imaging showed no evidence of hemodynamically signiﬁcant ste-
nosis (mean peak velocity ratio: 1.2  0.4). Stent fractures were observed in 4 stents (22%, type I
[6%], type II [16%]) and were clinically silent in all cases.
Conclusions Vascular complications after TAVI can be treated percutaneously as a bailout procedure
with a high rate of technical success, and clinical outcomes are comparable to patients without vascular
complications. Stent patency is high during follow-up, although stent fractures require careful scrutiny.
(J Am Coll Cardiol Intv 2012;5:515–24) © 2012 by the American College of Cardiology Foundation
From the *Department of Cardiology, Swiss Cardiovascular Center Bern, University of Bern, Bern, Switzerland; †Department of
Clinical, Interventional Angiology, Swiss Cardiovascular Center Bern, University of Bern, Bern, Switzerland; ‡Department of
Cardiovascular Surgery, Swiss Cardiovascular Center Bern, University of Bern, Bern, Switzerland; §Department of Diagnostic,
Interventional, and Pediatric Radiology, Bern University Hospital, University of Bern, Bern, Switzerland; and the Department of
Anesthesiology and Pain Therapy, Bern University Hospital, University of Bern, Bern, Switzerland. This study was supported by
research grants from Bern University Hospital and a grant of the Swiss National Science Foundation to Dr. Windecker (SNF
Grant 32003B_135807). Dr. Stortecky has received a research fellowship funded by the Swiss National Science Foundation. Dr.
Wenaweser received lecture and consultant fees from Edwards Lifesciences and Medtronic CoreValve. Dr. Huber is a proctor for
Edwards Lifesciences and a consultant for Medtronic. Dr. Khattab is a proctor for Medtronic and Edwards Lifesciences. Dr.
Buellesfeld is a trainer and consultant for Medtronic. Dr. Eberle received lecture honoraria from Medtronic CoreValve. Dr.
Windecker also received lecture and consultant fees from Edwards Lifesciences and Medtronic. All other authors have reported
that they have no relationships relevant to the contents of this paper to disclose.Manuscript received September 29, 2011; revised manuscript received December 2, 2011, accepted January 11, 2012.
m
A
T
t
a
o
t
p
c
t
r
a
t
M
s
p
g
s
D
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 5 , 2 0 1 2
M A Y 2 0 1 2 : 5 1 5 – 2 4
Stortecky et al.
Percutaneous Treatment of TAVI-Related Access Site Complications
516Transcatheter aortic valve implantation (TAVI) for treat-
ment of severe aortic stenosis improves survival compared
with medical treatment alone among patients considered
not suitable candidates for surgery (1) and is noninferior to
surgical aortic valve replacement in terms of survival among
selected very high-risk patients (2). Pre-operative evaluation
of the vascular access site aims to define vessel size,
tortuosity, and extent of calcification to identify the best
vascular access site and to minimize the risk of complica-
tions. Notwithstanding, vascular injury and access site
complications remain the most frequent adverse event
occurring in 12% to 30% of cases (1,3,4), which may result
in life-threatening bleeding and require surgical or interven-
tional treatment in most cases. Moreover, major vascular
complications among patients undergoing TAVI have been
identified as predictors of mortality underscoring the serious
nature of this adverse event (1,3).
Surgical repair of vascular complications is common
practice, but it is associated with patient discomfort, treat-
ment delay, prolonged hospitalization, and the risk of
wound infections (5,6). A percutaneous treatment strategy,
including the implantation of covered stent grafts for
secondary vessel closure in case
of incomplete arteriotomy clo-
sure, vessel perforation, rupture,
or dissection is effective to rap-
idly stop severe bleeding, thereby
mitigating the consequences of this
complication. However, there is
concern that covered stent grafts
implanted into the iliofemoral ar-
tery may be prone to stent fracture
and flow obstruction due to the superficial anatomical
location with risk of external compression and exposure to
bending forces. Therefore, the purpose of the present study
was to evaluate the feasibility and safety of percutaneous
management of vascular complications during transfemoral
TAVI.
Methods
Patient population. Between August 2007 and July 2010,
149 high-risk patients with symptomatic, severe aortic valve
stenosis underwent transfemoral TAVI using a purely per-
cutaneous approach at a single institution. Figure 1 sum-
arizes the flow of patients included into the present study.
ll patients underwent comprehensive evaluation before
AVI using a standardized protocol during a short hospi-
alization, including left and right heart catheterization,
ortography, transthoracic and transesophageal echocardi-
graphy, and computed tomography (CT) angiography of
he chest, abdomen, and pelvis before the procedure as
reviously described (7,8). An interdisciplinary team of
Abbreviations
and Acronyms
CT  computed tomography
TAVI  transcatheter aortic
valve implantation
VARC  Valvular Academic
Research Consortiumardiac surgeons and interventional cardiologists reviewed dhe cases and agreed on subsequent treatment allocation. The
egistry was approved by the local medical ethics committee,
nd all patients signed informed, written consent.
Procedure. Transfemoral TAVI was performed using either
he Medtronic CoreValve (Medtronic, Inc., Minneapolis,
innesota) or the Edwards Sapien valve (Edwards Life-
ciences, Irvine, California). Vascular access was obtained by
uncture of the common femoral artery under fluoroscopic
uidance. After pre-dilation of the vessel with a 9-F vascular
heath, a 10-F ProStar XL closure device (Abbott Vascular
evices, Redwood City, California) was inserted, sutures
Peripheral Vascular Complicaons
Among Paents Undergoing Percutaneous Transfemoral TAVI 
(N=27)
Delayed Surgical Repair (n=2)
Manual Compression (n=2)
STUDY POPULATION
Percutaneous Treatment of Peripheral Vascular Complicaons
(N=23)
Death (n=2)
Living abroad (n=1)
Nursing Home (n=1)
Peripheral Assessment During Follow Up 
(N=17)
Fluoroscopy 
(N=17)
Duplex ultrasound 
(N=17)
CT Scan 
(n=11)
Impaired Renal Funcon (n=6)
Transfemoral TAVI for Severe Aorc Stenosis
(N=171)
Percutaneous Transfemoral AVI 
(N=149)
Death before Valve Implantaon 
(n=2)
Surgical Access (n=20)
Percutaneous Treatment With Stent Gra Implantaon
(N=21)
Failure of percutaneous treatment
management
→urgent surgical repair (n=2)
Figure 1. Patient Flow
Patient ﬂow of patients included into the present study. AVI  aortic valve
implantation; CT  computed tomography; TAVI  transcatheter aortic
valve implantation.eployed, needles removed, and sutures secured using the
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517pre-closure technique (9). Following this, an 18-F delivery
sheath was inserted in case of the CoreValve bioprosthesis
(26 and 29 mm) and a 22- or 24-F sheath was inserted in
case of the Sapien valve (23 and 26 mm). More recently, the
delivery sheath of the Sapien valve was reduced to 18- and
19-F with the advent of the Edwards Sapien XT device
(Edwards Lifesciences).
After successful transfemoral valve implantation, cathe-
ters were removed and access site closure was completed. In
the first 65 transfemoral patients, the access site was closed
by unprotected tightening of the pre-closed knot of the
ProStar device (Abbott Vascular Devices). Subsequently, we
adopted the systematic use of a crossover technique as
described by Sharp et al. (10). In brief, a stiff wire (Magic
Torque Guide-wire, 0.035 inch, Boston Scientific Corp.,
Natick, Massachusetts, or Terumo Stiff Radifocus Guide-
wire, 0.035 inch, Terumo Medical Corporation, Terumo,
Somerset, New Jersey) was advanced from the contralateral
groin into the ipsilateral delivery sheath using a 5-F Judkins
right or short-tipped pigtail catheter. Then, an appropri-
ately sized peripheral vascular balloon (6 to 10 mm) was
advanced through a 6- to 7-F crossover sheath (e.g.,
Terumo Destination Guiding Sheath) and placed in the
common iliac artery just proximal to the introducer sheath.
Low-pressure balloon inflation was performed to occlude
the iliac vessel and provide a bloodless dry field for access
site closure. Following this, the vascular access sheath was
removed and the pre-laid sutures of the ProStar device
(Abbott Vascular Devices) were tied in place. The result was
checked by contrast angiography via the crossover sheath.
In case of vessel rupture, dissection, and incomplete
suture closure, the guidewire was advanced across the site of
vascular injury into the distal superficial femoral artery to
allow for prolonged balloon occlusion of the vessel. In case
of persistent bleeding, rupture, or flow-limiting dissection,
percutaneous treatment with a self-expandable covered
(Fluency Plus, Bard Peripheral Vascular, Tempe, Arizona)
or uncovered stent graft (Cristallo Ideale, Self Expanding
Stent System, Medtronic, INVAtec, Roncadelle, Italy) was
performed. The covered stent graft consists of a self-
expanding nitinol stent platform, encapsulated with 2 ultra-
thin expanded polytetrafluoroethylene layers. Covered stent
grafts were available in lengths between 40 and 80 mm and
diameters between 7 and 10 mm, constrained in an 8- to
10-F delivery system designed to accept a 0.035-inch
guidewire. The stent graft was placed through a 9-F
intravascular sheath following removal of the peripheral
vascular balloon and crossover sheath. Then, the stent graft
was advanced over the stiff guidewire and placed under
fluoroscopic guidance using anatomic landmarks.
Patients undergoing TAVI received a loading dose of
clopidogrel (300 mg) and acetylsalicylic acid (100 mg) the
day before the intervention. Clopidogrel was maintained at
a dose of 75 mg/day for the duration of 6 months after TAVIand acetylsalicylic acid 100 mg was prescribed indefinitely.
Patients requiring oral anticoagulation for various indications
also received acetylsalicylic acid 100 mg indefinitely.
Endpoint deﬁnitions. Clinical adverse events were adjudi-
cated by a team of interventional cardiologists and cardiac
surgeons according to the Valvular Academic Research
Consortium (VARC) endpoint definitions described in
detail elsewhere (11). Vascular complications were defined
as major whenever vascular injury, leading to death, trans-
fusion of more than 4 blood units, unplanned percutaneous
or surgical intervention, or irreversible end organ damage
occurred. Minor vascular complications were defined as any
vascular injury requiring blood transfusions 4 U not
resulting in unplanned percutaneous or surgical interven-
tion, as well as percutaneous access site closure failure
resulting in interventional or surgical correction. Bleeding
events were assessed as life-threatening or disabling: 1) in
case of bleeding into a critical area or organ; 2) bleeding
causing hypovolemic shock or requiring vasopressors or
surgery; or 3) with an overt source of bleeding with a
decrease in hemoglobin 5 g/dl or packed red blood cells
transfusion 4 U. Major bleeding was considered in the
setting of overt bleeding associated with a decrease in the
hemoglobin level of at least 3.0 g/dl. For the definition of
death, myocardial infarction, stroke, and kidney injury,
we refer to previous reports. Major adverse cerebro-
cardiovascular events were defined as death, myocardial
infarction, or major stroke (7,8).
Data collection and follow-up. Adverse events were assessed
n hospital, and regular clinical follow-up was performed
t 1, 6, and 12 months, and yearly thereafter by means of
clinical visit or a standardized telephone interview. All
uspected events were adjudicated by an unblinded clin-
cal event committee. Baseline clinical and procedural
haracteristics and all follow-up data were entered into a
edicated database, held at an academic clinical trials unit
CTU Bern, Bern University Hospital, Switzerland) re-
ponsible for central data audits and maintenance of the
atabase.
All patients with percutaneous management of vascular
omplications underwent follow-up assessment of the pe-
ipheral vascular site by clinical assessment, fluoroscopy, and
uplex ultrasonography. In addition, multislice CT angiog-
aphy was scheduled in all patients without renal failure
glomerular filtration rate 40 ml/min/1.73 m2). Cine
images were obtained by use of biplane radiography of the
vascular access site with at least 2 orthogonal projections.
Implanted stents were visualized using the stent boost
technique under high magnification (15) to detect stent
fractures. All images were evaluated by a team consisting of
a peripheral vascular disease specialist and an interventional
cardiologist to grade the presence of stent fractures accord-
ing to the classification of Jaff et al. (12). Duplex ultrasonog-
raphy was performed in all patients under fasting conditions
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518to assess patency and flow across the implanted stent grafts.
Restenosis was defined as peak velocity ratio (calculated as
intrastenotic peak systolic velocity divided by proximally
recorded peak systolic velocity) 2.4 (13). Multislice con-
trast CT angiography allowed assessment of stent integrity
and patency.
Statistical analysis. Continuous variables are presented as
mean  SD and were compared using Student t test
analysis. Categorical data are expressed as frequency
(percentages), and Fisher exact tests or Pearson chi-
square tests were used for baseline and procedural com-
parisons. Outcome data were compared using univariate
logistical regression analysis, and in case of no (0) events,
relative risks were computed with a continuity correction
of 0.5 along with respective p values. All statistical
analyses were performed using SPSS statistical package
(version 17.0, SPSS Inc., Chicago, Illinois). All p values
are the results of 2-tailed tests and values 0.05 were
considered statistically significant.
Table 1. Baseline Clinical Characteristics
Percutaneou
Complic
Managemen
Age, yrs 85
Female 15 (6
Body mass index, kg/m2 27
Cardiac risk factors
Diabetes mellitus 2 (9
Hypercholesterolemia 12 (5
Hypertension 19 (8
Past medical history
Previous myocardial infarction 6 (2
Previous CABG 5 (2
Previous PCI 4 (1
Previous cerebrovascular event 1 (4
Peripheral vascular disease 3 (1
Chronic obstructive lung disease 2 (9
Symptoms
NYHA functional class I 2 (9
NYHA functional class II 4 (1
NYHA functional class III 16 (7
NYHA functional class IV 1 (4
Risk assessment
Logistic EuroSCORE, % 31
STS score, % 6.2
Cardiac catheterization
Coronary artery disease 13 (5
Left ventricular ejection fraction, % 48
Aortic valve area, cm2 0.58
Mean transaortic gradient, mm Hg 45
Values are mean SD or n (%). *Continuous variables were compared
CABG coronary artery bypass graft; EuroSCORE European SystePCI percutaneous coronary intervention; STS Society of Thoracic SurgeoResults
Patient population. Between August 2007 and June 2010,
149 patients underwent transfemoral TAVI using a purely
percutaneous technique and are subject of the present
report (Fig. 1). A total of 27 (18%) patients suffered from
at least 1 vascular complication, and 23 patients at-
tempted to undergo percutaneous treatment with covered
or uncovered stent implantation. Baseline clinical char-
acteristics of patients with and without percutaneous
vascular complication management are shown in Table 1.
With the exception of a higher body mass index (27  4
kg/m2 vs. 25  4 kg/m2, p  0.04) and logistic
uroSCORE (European System for Cardiac and Cere-
rovascular Events) (31  19% vs. 22  15%, p  0.02),
s well as trend toward a higher prevalence of patients in
ew York Heart Association functional class III (70% vs.
8%, p  0.07) among patients with percutaneous
ascular complication management, there were no signif-
ular
23)
No Vascular Complication
(n  122) p Value*
84 5 0.16
72 (59) 0.65
25 4 0.04
30 (25) 0.11
68 (56) 0.82
99 (81) 1.00
21 (17) 0.38
22 (18) 0.77
25 (21) 1.00
12 (10) 0.69
20 (16) 1.00
23 (19) 0.37
14 (12) 1.00
37 (30) 0.31
58 (48) 0.07
13 (11) 0.70
22 15 0.02
6.3 6 0.89
72 (59) 0.82
52 14 0.19
0.54 0.2 0.43
45 16 0.89
Student t test and categorical variables using Fisher exact test.
rdiac Operative Risk Evaluation; NYHANewYork Heart Association;s Vasc
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519icant differences between the 2 groups in terms of cardiac
risk factors, past medical history, and aortic valve stenosis
severity.
Procedural characteristics and outcome. The type and man-
gement of all 27 vascular complications are summarized in
able 2. They consisted of incomplete arteriotomy closure
n  19, 70%), vascular dissection (n  3, 11%), arterial
erforation (n 3, 11%), arterial occlusion (n 1, 4%), and
pseudoaneurysm (n  1, 4%) and were classified as VARC
major in 9 (6%) and as VARC minor vascular complications
in 18 (12%) patients. VARC major complications were
Table 2. Vascular Complications After Percutaneous Transfemoral TAVI
Patient #
Sheath
Size, F Type of Vascular Complication
Severity
(VARC) Si
1 18 Common femoral artery perforation Major Access si
2 5 Common femoral artery occlusion Major Contralat
3* 18 Incomplete arteriotomy closure Major Access si
4 18 Common femoral artery dissection Major Access si
5 18 Common femoral artery dissection Major Access si
6 18 Incomplete arteriotomy closure Minor Access si
7 18 Incomplete arteriotomy closure Minor Access si
8 24 Incomplete arteriotomy closure Minor Access si
9 22 Incomplete arteriotomy closure Minor Access si
10 24 Common iliac artery perforation Major Access si
11 18 Common iliac artery dissection Major Access si
12 18 Incomplete arteriotomy closure Minor Access si
13 24 External iliac artery perforation Major Access si
14 18 Incomplete arteriotomy closure Minor Access si
15 18 Incomplete arteriotomy closure Minor Access si
16 24 Incomplete arteriotomy closure Minor Access si
17 18 Incomplete arteriotomy closure Minor Access si
18 18 Incomplete arteriotomy closure Minor Access si
19 18 Incomplete arteriotomy closure Minor Access si
20 18 Incomplete arteriotomy closure Minor Access si
21 18 Incomplete arteriotomy closure Minor Access si
22 24 Pseudoaneurysm Major Access si
23 22 Incomplete arteriotomy closure Minor Access si
24 18 Incomplete arteriotomy closure Minor Access si
25 18 Incomplete arteriotomy closure Minor Access si
26 18 Incomplete arteriotomy closure Minor Access si
27 19 Incomplete arteriotomy closure Minor Access si
*Patient #3 had life-threatening bleeding leading to VARC major access site complication.TAVI transcatheter aortic valve implantation; VARC Valvular Academic Research Consortium.more common among patients undergoing TAVI using 22-
or 24-F delivery sheaths (n  3, 25%) as compared to those
reated through 18- or 19-F delivery sheaths (n  6, 4%;
 0.0001) (Fig. 2A). After the systematic implementation
f the vascular crossover technique, the rate of VARC major
ascular complications decreased from 12% (n  8) to 1%
n  1) (Fig. 2B).
Percutaneous stent graft implantation was successful in
1 of 23 (91%) attempted cases, but failed in 2 patients due
o excessive tortuosity with inability to crossover from the
ontralateral site, and those patients underwent urgent
Crossover
Technique
for Closure
Treatment
Strategy Comments
No Delayed surgery Uneventful percutaneous access site
closure. Hemodynamic instability 1 h
after the intervention. Detection of
perforated common femoral artery on
CT angiography. Urgent surgical repair.
e No Percutaneous Uncovered stent implantation 6  30 mm
No Percutaneous Covered stent implantation 8  40 mm
No Percutaneous Uncovered stent implantation 8  30 mm
No Percutaneous Covered stent implantation 10  60 mm
No Percutaneous Covered stent implantation 8  40 mm
No Percutaneous Covered stent implantation 8  40 mm
No Percutaneous Covered stent implantation 8  60 mm
No Percutaneous Covered stent implantation 8  40 mm
No Urgent surgery Perforation of iliofemoral artery.
Unsuccessful crossover due to severe
tortuosity. Urgent surgical repair.
No Urgent surgery Dissection and active bleeding of common
iliac artery. Unsuccessful crossover due
to severe tortuosity. Urgent surgical
repair.
No Percutaneous Covered stent implantation 8  40 mm
No Percutaneous Covered (8  40 mm) and uncovered
(8  40 mm) stent implantation
Yes Compression Manual compression
Yes Percutaneous Covered stent implantation 8  40 mm
Yes Percutaneous Covered stent implantation 8  40 mm
Yes Compression Manual compression
Yes Percutaneous Covered stent implantation 7  40 mm
Yes Percutaneous Covered stent implantation 8  40 mm
Yes Percutaneous Covered stent implantation 8  40 mm
Yes Percutaneous Covered stent implantation 8  40 mm
Yes Delayed surgery Spontaneous large hematoma in right
groin on day 17. Detection of a large
pseudoaneurysm. Successful surgical
repair.
Yes Percutaneous Covered stent implantation 8  40 mm
Yes Percutaneous Covered stent implantation 8  40 mm
Yes Percutaneous Covered stent implantation 10  40 mm
Yes Percutaneous Covered stent implantation 8  40 mm
Yes Percutaneous Covered stent implantation 8  40 mmte
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520surgical repair. Two other patients underwent delayed
surgery due to development of a retroperitoneal hematoma
on day 1 and a pseudoaneurysm on day 17, respectively, and
2 patients were treated by manual compression. Percutane-
ous management of vascular complications was performed
ad hoc in 20 patients, whereas 1 patient was treated 1 day
after TAVI. This patient, requiring delayed treatment the
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521access site complications and were treated by implantation
of a self-expandable covered stent graft (Fluency Plus, Bard
Peripheral Vascular) (Fig. 3). One patient received an
additional uncovered stent to reconstruct a femoral artery
dissection. Balloon dilation after self-expandable stent graft
placement was performed in 5 patients (24%) to ensure full
stent expansion.
Procedural characteristics are summarized in Table 3.
There were no differences in terms of type of anesthesia and
need for blood transfusions between patients requiring
percutaneous vascular complication management and those
without complications. We observed a significant difference
in fluoroscopy time (25  9 min vs. 21  8 min, p  0.02)
ithout differences in procedural time or contrast media use
mong patients requiring percutaneous vascular complica-
ion management.
Clinical outcome. The in-hospital course was similar for
atients with percutaneous vascular complication manage-
ent and for those without in terms of hospital duration
9.9  7 days vs. 9.5  4 days, p  0.76) and need for
acked red blood cell transfusion transfusions (0.4  0.9 U
s. 0.2  0.7 U, p  0.33). Clinical outcome at 30 days is
ummarized in Table 4. There were no differences between
atients with percutaneous vascular complication manage-
ent and those without for any VARC-defined endpoint,
ncluding mortality, myocardial infarction, stroke, and renal
ailure. A significant difference in terms of life-threatening
leeding (17% vs. 4%, p  0.04) was mainly driven by the
patients with unsuccessful percutaneous treatment of
Table 3. Procedural Characteristics
Percutaneous Vascular
Complication
Management
(n  23)
No Vascular
Complication
(n  122) p Value*
Procedure time, min 78 20 84 37 0.30
Fluoroscopy time, min 25 9 21 8 0.02
Amount of contrast, ml 296 109 266 100 0.20
Anesthesia 8 (35) 31 (25) 0.44
Valve type 0.003
Medtronic CoreValve 16 (70) 114 (93)
Edwards Sapien THV 7 (30) 8 (7)
Sheath size 0.02
18- and 19-F 18 (78) 116 (95)
22- and 24-F 5 (22) 6 (5)
Revascularization
Concomitant PCI 3 (13) 19 (16) 1.00
Staged PCI 3 (13) 14 (12) 0.74
Blood transfusions
Number of PRBC 2 U 4 (17) 8 (7) 0.10
Values are mean SD or n (%). *Continuous variables were compared using Student t test and
categorical variables using Fisher exact test.
PCI percutaneous coronary intervention; PRBC packed red blood cell transfusion; THV
transcatheter heart valve.ascular complication following urgent surgical repair of theascular access site. Major vascular complications as part of
he VARC combined safety endpoint were more prevalent
n the percutaneous vascular complication management
roup. When excluding major vascular complications from
he VARC combined safety endpoint (modified combined
afety endpoint), numerical differences between both groups
ere less pronounced.
Follow-up imaging of vascular complications. After a me-
dian follow-up of 10.9 months (interquartile range: 6.8 to
22.6 months), 17 of 21 patients with implanted peripheral
stent grafts underwent clinical assessment, biplane fluoros-
copy, and duplex ultrasonography of the intervened site
(Fig. 4). Multislice CT of the vascular region of interest
was performed in the absence of chronic renal failure in
11 of 17 patients. Duplex ultrasonography showed pa-
tency of all stent grafts and the absence of restenosis
within the stent as determined by a peak velocity ratio of
2.4 in all patients. One patient showed a stenotic flow
pattern (Vmax  4.05 m/s) in the deep femoral artery
istal to the implanted covered stent graft. However,
ultislice CT revealed a patent femoral artery bifurcation
istal to the stent, and the patient did not experience
ntermittent claudication or other symptoms. Biplane
uoroscopy revealed full stent integrity without signs of
ractures in 14 of 18 stent grafts (78%). A grade I fracture
as observed in 1 stent (6%), and a grade II fracture was
resent in 3 stent grafts (16%) according to the classifi-
Table 4. Clinical Outcome at 30 Days
Percutaneous
Vascular
Complication
Management
(n  23)
No Vascular
Complication
(n  122) p Value*
All-cause mortality 1 (4) 9 (7) 0.60
Cardiovascular mortality 0 (0) 6 (5) 0.55
Myocardial infarction 0 (0) 4 (3) 0.74
Stroke
Major 1 (5) 6 (5) 0.98
TIA 0 (0) 1 (1) 0.77
MACCE 2 (9) 10 (8) 1.00
Bleeding
Life-threatening 4 (17) 5 (4) 0.04
Major 8 (35) 30 (25) 0.31
Kidney injury 0.96
None 21 (91) 108 (89)
Stage 1 2 (9) 10 (8)
Stage 2 0 (0) 1 (1)
Stage 3 0 (0) 3 (2)
VARC-combined safety endpoint 7 (30) 16 (13) 0.06
VARC-modiﬁed combined safety endpoint 5 (22) 16 (13) 0.33
Values are n (%). *Outcome variables were compared using logistical regression analysis and in
case of no (n 0) events, respective p valueswere calculated after correction for continuity of 0.5.
MACCEmajor adverse cardiac and cerebrovascular event(s); TIA transient ischemic attack;VARC Valvular Academic Research Consortium.
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522cation proposed by Jaff et al. (12). There were no grades
III, IV, or V fractures. Multislice CT confirmed stent
patency in 12 of 12 stent grafts (100%) without evidence
of angiographic restenosis.
Discussion
The results of the present study indicate that percutaneous
treatment of vascular complications after TAVI is feasible
and is associated with high technical success. Clinical
outcome of patients undergoing percutaneous management
of vascular complications is comparable to those without
vascular complications, and follow-up imaging shows patent
stent grafts in all patients without need for reintervention
during follow-up.
Vascular complications remain a principal limitation of
TAVI as they may result in life-threatening bleeding and
hemodynamic compromise among patients considered high
risk for the procedure itself. The serious nature of major
vascular complications is further underscored by the in-
creased risk of mortality in recent studies (1). The incidence
of vascular complications amounted to 18% consisting of
VARC major in 6% of patients and VARC minor vascular
complications in 12.1% of patients in this transfemoral
cohort. Vascular complications were more common among
patients treated using larger (22- or 24-F) delivery sheaths,
but they were reduced with the implementation of the
systematic crossover technique with temporary balloon oc-
clusion of the common iliac artery during vascular closure of
Figure 4. Imaging Follow-Up Assessment
Imaging follow-up assessment of vascular injury site by duplex ultrasonograph
and the absence of restenosis. Biplane ﬂuoroscopy showing no evidence of stthe access site (Fig. 2).The frequency of vascular complications in the present
study compares well with previous reports using the VARC
endpoint definitions in predominantly high-risk patient
populations (14,15). Recently published data from the
PARTNER B (Placement of Aortic Transcatheter Valves
[Cohort B]: Transfemoral TAVI vs. Medical Management)
trial observed any vascular complication in 30.7% and major
vascular complication in 16.2% of patients considered inop-
erable (1), whereas patients enrolled into the transfemoral
cohort of PARTNER A (Placement of Aortic Transcath-
eter Valves [Cohort A]: TAVI vs. Surgical AVR) trial
experienced any vascular complications in 23% and major
vascular complications in 14% of patients in the as-treated
analysis (2). Of note, patients included into the PARTNER
trials were treated with 22- to 24-F access sheaths and did
not benefit from the newer generation devices currently
available. Gurvitch et al. (14) reported vascular access site
complications in 18.5% of 205 patients undergoing trans-
femoral TAVI with the Edwards Sapien prosthesis with
VARC major in 9.8% and VARC minor access site com-
plications in 8.8% of patients. In this study, major vascular
access site complications were attributed to the need for
blood transfusions of 4 U in 84% of cases. Conversely,
only 1 patient had a VARC major access site complication
due to bleeding and blood transfusion of 4 packed red
blood cell transfusions in the present study, whereas vessel
perforation, dissection, and occlusion were the causes of
VARC major access site complications in the remaining
and multislice computed tomography (B) showing patency of the stent graft
ctures (C).y (A)patients (Table 2).
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523Percutaneous treatment of vascular complications is able
to decrease in-hospital complications, such as wound infec-
tion, femoral neuropathy, and lymphatic fistula formation
(6,16); increases patient comfort; and seems to be more
cost-effective than surgical arterial cut down, due to rapid
mobilization and earlier hospital discharge (5,6). Currently
available devices for suture-mediated percutaneous closure
of the arteriotomy achieve high rates of technical success in
up to 90% of patients, even among elderly populations
undergoing TAVI using large-bore catheters (17). How-
ever, failure of arteriotomy closure and other vascular
complications, including vessel perforation, dissection, and
occlusion remain matters of concern. The high prevalence of
peripheral arterial disease in conjunction with potent anti-
coagulation and antiplatelet regimens during the procedure
further increases the risk of these complications. Accord-
ingly, techniques to prevent or mitigate these adverse events
are of clinical importance and constitute an integral part of
any TAVI procedure. The crossover technique with tem-
porary balloon occlusion from the contralateral access site
allows a more controlled removal of TAVI delivery sheaths
(10) by lowering perfusion pressure and providing immedi-
ate access for percutaneous intervention in case of incom-
plete arteriotomy closure.
Major vascular complications after percutaneous cathe-
terization procedures are usually corrected by surgical treat-
ment, which is associated with high procedural success, low
morbidity, and low mortality (18). However, a percutaneous
technique with rapid repair of vascular injury repair is
desirable, especially among elderly high-risk patients under-
going TAVI, as it minimizes blood loss and the risk of
wound infections and allows for rapid mobilization and
earlier hospital discharge. Notwithstanding, the use of
covered stent grafts for secondary arteriotomy closure
should only be considered as a bailout procedure as vascular
access for future percutaneous catheterization procedures
might be impaired or limited to the contralateral site.
Moreover, the use of covered stent grafts for treatment of
vascular complications remains controversial due to unre-
solved questions relating to long-term patency and stent
integrity. Stent implantation for secondary vessel closure
after TAVI is performed in a vascular segment that not only
is exposed to biomechanical stress during physical motion of
the extremities, but also is amenable to external compressive
forces. Endovascular stent fractures, particularly when im-
planted into arteries that cross flexion points, have been well
documented in the literature and remain an issue of concern
(19,20). Especially the popliteal as well as common femoral
arteries are subject to forces, including compression, torsion,
and elongation, and the cumulative incidence of stent
fractures has been reported ranging from 15% to 28%
(21,22). We observed evidence of stent fractures in 4 of 18
stents (22%) in the present study. However, fractures were
minor and limited to Jaff class I (n  1, 6%) and class II(n  3, 16%) fractures with no single case of high-grade
stent fractures. Moreover, investigation by duplex ultra-
sonography and multislice CT showed patent stent grafts
without evidence of restenosis in any patient (23). Further-
more, none of the patients was symptomatic or required
additional surgical or interventional therapy after secondary
vessel closure.
Study limitations. The present report summarizes the expe-
ience of a single institution with only a limited number of
atients undergoing percutaneous management of vascular
omplications following TAVI. Therefore, the results are
xploratory and require confirmation in larger studies during
onger term follow-up. However, the rates of VARC-
efined vascular complications as well as clinical outcomes
re comparable with previous reports. The inclusion of
atients from the very early experience may have resulted in
n overestimation of the rate of vascular complications due
o an ongoing learning curve. Thus, we did not systemati-
ally use the vascular crossover technique during the first 65
atients of the present cohort. This resulted in a higher
requency of VARC major vascular complications among
atients in whom crossover-assisted arteriotomy closure had
ot been used. Finally, the study does not address the
hanging incidence and type of vascular access site compli-
ations due to the advent of novel and smaller vascular
ccess sheaths.
onclusions
Vascular complications after TAVI can be treated percuta-
neously as a bailout procedure with a high rate of technical
success and clinical outcomes comparable to patients with-
out vascular complications. Stent patency and integrity is
high during follow-up, although stent fractures require
careful scrutiny.
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